Literature DB >> 20128686

Immunohistochemical analysis of kallikrein-related peptidases in the normal kidney and renal tumors: potential clinical implications.

Manal Gabril1, Nicole M White, Madeleine Moussa, Tsz-fung F Chow, Shereen M Metias, Eman Fatoohi, George M Yousef.   

Abstract

Kallikrein-related peptidases (KLKs) have been shown to be differentially expressed in various malignancies and shown to be useful tumor markers. Previous immunohistochemistry (IHC) analysis demonstrated that KLKs 5, 6, 10, and 11 have a potential prognostic significance in renal cell carcinoma (RCC). To further explore the significance of KLKs, we examined KLKs 1, 6, 7, and 15 in different subtypes of renal tumors. KLK1 has stronger expression in high grade compared to low grade clear cell RCC. However, KLK6 and KLK7 show strong expression in low grade in contrast to high grade clear cell RCC. Furthermore, the expression of KLK7 can distinguish between oncocytoma and chromophobe RCC. Oncocytoma showed diffuse, strong granular cytoplasmic staining, but chromophobe RCC showed focal weak homogeneous cytoplasmic stain. The pattern of staining of different KLKs can also be helpful in differentiating some of the subtypes of renal tumors. Our results show the potential ability of KLKs to serve as diagnostic markers and expand previous data about the prognostic significance of KLKs in kidney cancer. In addition, our study is the first to show the ability of KLK staining to distinguish various types of kidney cancers when morphology is similar.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20128686     DOI: 10.1515/BC.2010.025

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  8 in total

1.  Expression of Kallikrein-Related Peptidase 6 in Primary Mucosal Malignant Melanoma of the Head and Neck.

Authors:  Julia Thierauf; Johannes A Veit; Jochen K Lennerz; Stephanie E Weissinger; Annette Affolter; Johannes Döscher; Christoph Bergmann; Andreas Knopf; Jennifer Grünow; Lisa Grünmüller; Cornelia Mauch; Peter K Plinkert; Thomas K Hoffmann; Jochen Hess
Journal:  Head Neck Pathol       Date:  2016-11-14

2.  Expression and clinical significance of KLK5-8 in endometrial cancer.

Authors:  Shu Lei; Qi Zhang; Fufen Yin; Xiangjun He; Jianliu Wang
Journal:  Am J Transl Res       Date:  2019-07-15       Impact factor: 4.060

3.  METTL13 inhibits progression of clear cell renal cell carcinoma with repression on PI3K/AKT/mTOR/HIF-1α pathway and c-Myc expression.

Authors:  Zhuonan Liu; Tianshui Sun; Chiyuan Piao; Zhe Zhang; Chuize Kong
Journal:  J Transl Med       Date:  2021-05-13       Impact factor: 5.531

4.  Kallikrein-related peptidase 6 regulates epithelial-to-mesenchymal transition and serves as prognostic biomarker for head and neck squamous cell carcinoma patients.

Authors:  Carola H Schrader; Markus Kolb; Karim Zaoui; Christa Flechtenmacher; Niels Grabe; Klaus-Josef Weber; Thomas Hielscher; Peter K Plinkert; Jochen Hess
Journal:  Mol Cancer       Date:  2015-05-20       Impact factor: 27.401

5.  Diagnostic and prognostic biomarker potential of kallikrein family genes in different cancer types.

Authors:  Prashant D Tailor; Sai Karthik Kodeboyina; Shan Bai; Nikhil Patel; Shruti Sharma; Akshay Ratnani; John A Copland; Jin-Xiong She; Ashok Sharma
Journal:  Oncotarget       Date:  2018-04-03

6.  Aberrant expression of kallikrein-related peptidase 7 is correlated with human melanoma aggressiveness by stimulating cell migration and invasion.

Authors:  Tiphaine Delaunay; Lydia Deschamps; Meriem Haddada; Francine Walker; Antoninus Soosaipillai; Feryel Soualmia; Chahrazade El Amri; Eleftherios P Diamandis; Maria Brattsand; Viktor Magdolen; Dalila Darmoul
Journal:  Mol Oncol       Date:  2017-08-11       Impact factor: 6.603

7.  Development and immunochemical evaluation of a novel chicken IgY antibody specific for KLK6.

Authors:  Georgia Sotiropoulou; Georgios Pampalakis; Evangelia Prosnikli; Gregory P Evangelatos; Evangelia Livaniou
Journal:  Chem Cent J       Date:  2012-12-05       Impact factor: 4.215

8.  Expression of kallikrein-related peptidase 7 is decreased in prostate cancer.

Authors:  Chong-Yu Zhang; Yu Zhu; Wen-Bin Rui; Jun Dai; Zhou-Jun Shen
Journal:  Asian J Androl       Date:  2015 Jan-Feb       Impact factor: 3.285

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.